After receiving seed funding from Sofinnova Partners in 2015, our company was founded around a pipeline of assets with best in class potential to make a positive impact on patients with cardio-renal diseases. Since then, we have raised $26 million in Series A financing led by Sofinnova Partners and Apple Tree Partners and, $60 million in Series B financing led by Venrock which included Andera Partners, Cormorant Asset Management, HBM Partners and Fresenius Medical Care Ventures GmbH.
We develop the right therapy for the right patient to address significant, unmet medical needs. Our pipeline is currently focused on treating the life-threatening conditions of Chronic Kidney Disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride induced Acute Pancreatitis, both conditions that do not have an approved therapy.
Marc De Garidel
Chief Executive OfficerBio +
Marc de Garidel is the Chief Executive Officer of Corvidia Therapeutics since April 2018. Prior to joining Corvidia, Marc was the Chairman and Chief Executive Officer of Ipsen SA from 2010 to 2016, where he led the company through a significant transformation and spearheaded the growth of operations in the United States. He remains Chair of the Board of Directors for Ipsen SA. Before his experience at Ipsen SA, Marc spent 15 years with the multinational biopharmaceutical company, Amgen. Based primarily in Europe, Marc helped Amgen establish and build a significant business in nephrology and oncology, achieving leadership positions for several portfolio products. He began his career with Eli Lilly and Company where he worked in the United States, France and Germany. In Europe, Marc has played a prominent role in not-for-profit organizations such as co-Chairman of the Innovative Medicines Initiative (IMI) and Vice-President of the European Federation of Pharmaceutical Industries and Associations (EFPIA).’. Marc served on the Board of Directors for Vifor Pharmaceuticals AG between 2016 & 2018. Marc holds a master’s degree in civil engineering from École Spéciale des Travaux Publics in Paris, and an executive MBA from Harvard Business School. He is a recipient of the French Legion of Honor.
Chief Scientific OfficerBio +
In addition to being a founder of Corvidia Therapeutics, Michael Davidson also serves as the Chief Scientific Officer. Michael is a leading expert in the field of Lipidology and was named in The Best Doctors in America for the past 10 years. Michael was the co-founding Chief Medical Officer of Omthera Pharmaceuticals in 2008, which was later acquired by Astra Zeneca Pharmaceutical in 2013 for $443M. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Michael is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Michael received his BA/MS from Northwestern University and MD from The Ohio State University School of Medicine.
SVP, Head of RegulatoryBio +
In her role as Senior Vice President and Head of Regulatory Affairs, Gwyn Reis is responsible for establishing regulatory strategies for product development and registration. Gwyn joined Corvidia in July 2018 with over 30 years of experience in Regulatory Affairs. Her experience ranges from small companies (Ironwood, Indevus and Acambis) to large pharma (Boehringer Ingelheim and DuPont Merck Radiopharmaceuticals). In her most recent role at Ironwood, she established the regulatory department and oversaw the successful registration of Linzess. After graduating from the Philadelphia College of Pharmacy and Science and completing a residency in the pharmaceutical development group at the National Institute of Health, she started her regulatory journey as a program manager in the FDA’s Division of Cardio-Renal Drugs.
Executive Vice President, Head of Research & DevelopmentBio +
In addition to being one of Corvidia Therapeutic’s founders, Matt Devalaraja is Head of Research and Development. Matt is an inflammation biologist with more than 19 years of experience in drug discovery and development across multiple therapeutic areas. Prior to founding Corvidia, Matt was Director of Emerging Innovations Unit at AstraZeneca, where he enabled multiple clinical studies and developed the core hypothesis of precision cardiovascular therapeutics that formed the basis for Corvidia. He also was Head of Immunology Research, Pharmacokinetics and Toxicology groups at Human Genome Sciences, and was integral to the approval of Benlysta for Lupus and Raxibacumab for Anthrax. He started his career at Pfizer Ann Arbor and brought forth the first biologic program for Pfizer’s Global Immunology portfolio. As Head of Biologics Discovery at Pfizer Ann Arbor, he initiated multiple programs across various therapeutic areas including immunology and cardiovascular space—many of which are currently in various stages of clinical development. Currently, he is on the board of P2D Biosciences and is a founder of multiple startup biotech companies. Matt received his Ph.D. from the University of Kentucky and Post-Doctoral training at Vanderbilt University.
Executive Vice President, Head of Business DevelopmentBio +
Ram Aiyar is a founder at Corvidia where he serves as Executive Vice President and Head of Business development. In this role, he leads the finance, transactions, and operations activities. Prior to Corvidia, Ram was an Entrepreneur-in- Residence at BioHealth Innovation (BHI) and worked to successfully establish and shape early stage biotech startups in the Maryland region. He operated as interim management with the scientific founders in order to support product development and corporate development strategies. Ram has built multiple strategic alliances and partnerships with stakeholders from biopharma and academic communities. He brings over 15 years of diverse expertise with product development experience at Janssen Pharmaceuticals, finance experience at JP Morgan, and investment experience at Sofinnova Partners. Ram was the recipient of the Philip B. Hoffmann award for excellence in Science at Janssen for work done on erythropoietin agonists. He holds a MS/PhD from Drexel University and an MBA from INSEAD.
Sr. VP Clinical OperationsBio +
Douglas leads clinical operations at Corvidia Therapeutics. During his 22-year career in clinical development, Douglas has managed clinical activities for several successful products including Humira®, Lovaza®, Kengreal®, and Epanova®. Before joining Corvidia, Douglas served as Senior Vice President of Clinical Development and Project Management at Matinas BioPharma Holdings, Inc., where he built a clinical development team and managed development activities. Prior to working at Matinas, Douglas was the Senior Vice President of Clinical Development at Omthera, where he directed the clinical program for Epanova®, which lead to NDA approval. Douglas has a bachelor’s degree in biological sciences from Duke University and an MBA from Rutgers Business School.
VP FinanceBio +
Joe Chiapponi joined Corvidia in November 2018 as Vice President, Finance. With over 17 years in the biopharmaceutical industry, Joe has experience in raising capital, developing strategic financial plans and managing growth strategies. Prior to joining Corvidia, Joe has held several management positions for publicly traded companies. Most recently, Joe served as Vice President, Finance, Treasurer and Secretary at Verastem, Inc. Prior to working at Verastem, Inc., Joe held roles at Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), CombinatoRx and Dyax. Joe has a BS in Biology from Norwich University and an MBA from Suffolk University.
Board of Directors
Seth Harrison - Apple Tree Partners
Seth Harrison is the founder and managing partner of Apple Tree Partners. He has invested in life sciences since 1991. He is currently Chairman of ATP companies Braeburn Pharmaceuticals, Elstar Therapeutics, Limelight Bio and Stoke Therapeutics.
Seth’s prior investments include: Aileron Therapeutics, ArQule, Ceolacanth, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare International, Informed Access, SGX Pharmaceuticals, Syntimmune, Novus Therapeutics, Ultracision and ViroPharma. From 2002 to 2010, he also served on the board of the International Partnership for Microbicides. Prior to Founding ATP in 1999, Seth was a general partner at Oak Investment Partners, and before that a venture partner at Sevin Rosen Funds.
Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.
Graziano Seghezzi – Sofinnova Partners
Graziano Seghezzi is a Partner at Sofinnova Partners which he joined in 2006. He seeded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano also seeded and is on the Board of MISSION Therapeutics (United Kingdom), Crescendo Biologics (United Kingdom) and Hookipa Biotech (Austria). He promoted and is on the Board of BiovelocITA, Italy’s first biotech accelerator. Graziano started his career in venture capital in 2001 at Sofinnova Partners and then joined Index Venture in 2003. Prior to that, Graziano spent five years working in academic research at New York University’s School of Medicine, studying oncology and cardiovascular diseases. Graziano holds a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from RSM-Erasmus University (Netherlands).
Camille Samuels – Venrock
Cami Samuels focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Unity Biotechnology (UBX), Biolux, Corvidia, and recently stepped off the board of REGENXBIO (RGNX). Prior to Venrock, Cami was a Managing Director at Versant Ventures where she led investments in Kythera (KYTH), Novacardia (acquired by Merck), and ParAllele (acquired by Affymetrix), among many others. She was also a board observer at several companies including Genomic Health (GHDX), Jazz (JAZZ), Fluidigm (FLDM), and Syrrx (acquired by Takeda). Before Versant, she was responsible for business development at Tularik, Inc. (acquired by Amgen). Before Tularik, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar.
Marc De Garidel - Corvidia
Marc de Garidel is the Chief Executive Officer of Corvidia Therapeutics. Prior to joining Corvidia, Marc was the Chairman and Chief Executive Officer of Ipsen SA between 2010 and 2016 where he led the company through a significant transformation and spearheaded growth of operations in the United States. Prior to his experience at Ipsen SA, Marc spent 15 years with the multinational biopharmaceutical company Amgen. Based primarily in Europe, Marc helped Amgen establish and build a significant business in nephrology and oncology, achieving leadership positions for several portfolio products. He began his career with Eli Lilly and Company where he worked in the United States, France and Germany. In Europe, Marc has played a prominent role in not-for-profit organizations such as the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). He is currently the president of G5 Sante’. Marc served on the Board of Directors for Vifor Pharmaceuticals AG as a member and in 2018 as Vice Chair. He remains Chair of the Board of Directors for Ipsen SA. Marc holds a Master’s degree in civil engineering from École Spéciale des Travaux Publics in Paris and an executive MBA from Harvard Business School.
Sylvie Gregoire – Chair
Sylvie Grégoire, has over 25 years of international experience in the biotech and pharmaceutical industries. Sylvie was President of Shire Human Genetic Therapies (HGT), a business unit of Shire plc that focuses on Rare Diseases. Under her leadership, the business unit grew from $300M to $1.5B. Prior to joining Shire HGT, Sylvie was Executive Chairwoman of IDM Pharma and is currently the Executive Chair of EIP Pharma. She was previously CEO of GlycoFi, a privately held protein technology company, held executive positions at Biogen Inc., and worked at Merck & Co. in the US and abroad. Sylvie is also a non-executive member of the board of 2 public companies: NovoNordisk, a Danish pharmaceutical company and PerkinElmer an instrumentation and diagnostics company. She has a depth of experience in the management of commercial operations, manufacturing and regulatory affairs. Sylvie holds a Pharmacy degree from Laval University and a Doctorate degree in Pharmacy from SUNYAB.
Tyrell Rivers – Medimmune
Dr. Tyrell Rivers is an Executive Director within AstraZeneca’s corporate development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures where he specialized in biotechnology investing and, at Merck & Company, Inc. where he led the technical support for multiple commercial vaccine franchises, subsequently directing global business initiatives for accessing key technologies in research and development. Dr. Rivers earned his Bachelor of Science degree in chemical engineering from the Massachusetts Institute of Technology and his PhD in chemical engineering from University of Texas at Austin. He earned his MBA from the New York University Stern School of Business. Dr. Rivers serves on the Board of Directors for G1 Therapeutics (GTHX), Viela Bio and Armaron Bio Ltd. He is a board observer for several private companies.